Medically reviewed by Brendan Camp, MD Hidradenitis suppurativa (HS) is a chronic (long-term) condition that causes painful ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Biologics approved by the U.S. Food and Drug Administration to treat moderate to severe HS include adalimumab (Humira), bimekizumab-bkzx (Bimzelx), and secukinumab (Cosentyx). Infliximab (Remicade ...

Meanwhile among those treated with Cosentyx (secukinumab), 70% of patients achieved this, as measured using the Psoriasis Area Severity Index. In the trial, 1,048 patients randomly received either ...